Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinations.

Autor: Amano H; Department of Rare/Intractable Cancer Analysis Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan., Uchida H; Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan., Harada K; Department of Health Data Science, Tokyo Medical University, Tokyo, Japan., Narita A; Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan., Fumino S; Department of Pediatric Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan., Yamada Y; Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan., Kumano S; Department of Rare/Intractable Cancer Analysis Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Research & Development Group, Hitachi, Ltd., Tokyo, Japan., Abe M; Department of Rare/Intractable Cancer Analysis Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Research & Development Group, Hitachi, Ltd., Tokyo, Japan., Ishigaki T; Department of Rare/Intractable Cancer Analysis Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Research & Development Group, Hitachi, Ltd., Tokyo, Japan., Sakairi M; Department of Rare/Intractable Cancer Analysis Research, Nagoya University Graduate School of Medicine, Nagoya, Japan., Shirota C; Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan., Tainaka T; Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan., Sumida W; Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan., Yokota K; Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan., Makita S; Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan., Karakawa S; Department of Pediatrics, Hiroshima University, Graduate School of Biomedical and Health Sciences, Hiroshima, Japan., Mitani Y; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan., Matsumoto S; Department of Complex Systems Science, Graduate School of Information Science, Nagoya University, Nagoya, Japan., Tomioka Y; Department for the Promotion of Medical Device Innovation, National Cancer Center Hospital East, Chiba, Japan., Muramatsu H; Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan., Nishio N; Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan., Osawa T; Division of Integrative Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo, Japan., Taguri M; Department of Health Data Science, Tokyo Medical University, Tokyo, Japan., Koh K; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan., Tajiri T; Department of Pediatric Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Pediatric Surgery, Reproductive and Developmental Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan., Kato M; Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Matsumoto K; Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan., Takahashi Y; Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan., Hinoki A; Department of Rare/Intractable Cancer Analysis Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Jazyk: angličtina
Zdroj: Cancer science [Cancer Sci] 2024 May; Vol. 115 (5), pp. 1634-1645. Date of Electronic Publication: 2024 Feb 27.
DOI: 10.1111/cas.16116
Abstrakt: The urinary catecholamine metabolites, homovanillic acid (HVA) and vanillylmandelic acid (VMA), are used for the adjunctive diagnosis of neuroblastomas. We aimed to develop a scoring system for the diagnosis and pretreatment risk assessment of neuroblastoma, incorporating age and other urinary catecholamine metabolite combinations. Urine samples from 227 controls (227 samples) and 68 patients with neuroblastoma (228 samples) were evaluated. First, the catecholamine metabolites vanillactic acid (VLA) and 3-methoxytyramine sulfate (MTS) were identified as urinary marker candidates through comprehensive analysis using liquid chromatography-mass spectrometry. The concentrations of these marker candidates and conventional markers were then compared among controls, patients, and numerous risk groups to develop a scoring system. Participants were classified into four groups: control, low risk, intermediate risk, and high risk, and the proportional odds model was fitted using the L2-penalized maximum likelihood method, incorporating age on a monthly scale for adjustment. This scoring model using the novel urine catecholamine metabolite combinations, VLA and MTS, had greater area under the curve values than the model using HVA and VMA for diagnosis (0.978 vs. 0.964), pretreatment risk assessment (low and intermediate risk vs. high risk: 0.866 vs. 0.724; low risk vs. intermediate and high risk: 0.871 vs. 0.680), and prognostic factors (MYCN status: 0.741 vs. 0.369, histology: 0.932 vs. 0.747). The new system also had greater accuracy in detecting missing high-risk neuroblastomas, and in predicting the pretreatment risk at the time of screening. The new scoring system employing VLA and MTS has the potential to replace the conventional adjunctive diagnostic method using HVA and VMA.
(© 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
Databáze: MEDLINE
Externí odkaz: